Gilead Sciences, a privately owned company headquartered in the US, was founded in 1987. With approximately 13,690 employees, the company functions as a tier 1 media tech buyer. Gilead Sciences specializes in biotechnology research, focusing on bringing forward medicines for life-threatening diseases. The company's operations involve its employees collaborating through science to address medical challenges.
Gilead Sciences completed its acquisition of Arcellx on May 1, 2026, securing full ownership of a key experimental cancer therapy. The deal, valued at approximately $7.8 billion, saw Arcellx shareholders receive $115 per share in cash, alongside a non-transferable contingent value right (CVR) worth up to $5 per share, which is tied to the future sales performance of the lead asset.
Similar Companies
Subscribe for full access to Gilead Sciences's profile
Gilead Sciences offers 2 products in the media and telecoms services industry. Gilead Sciences's product portfolio comprises of search, social, and retail media.
Subscribe for full access to Gilead Sciences's products in full detail
Subscribe for full access to Gilead Sciences's revenue in full detail
Subscribe for full access to Gilead Sciences's products in full detail 
